However, once a person has ALS, diabetes does not affect how long they survive.
A new crystal structure shows a unique shape of Aβ in the arms of solanezumab. Exactly how this and other antibodies in the clinical pipeline grip Aβ could explain some differences in trial results.
Cellular, animal, and human studies suggest that the AD risk gene PICALM escorts Aβ through the blood-brain barrier.
In separate studies, researchers propose that high CSF ferritin and D-serine could become biomarkers to predict declining cognition in Alzheimer’s disease.
They overexpress Activin, allowing neurons to regrow axons in the central nervous system.
The motor neurons most sensitive to ALS require a microRNA cluster to survive, lest PTEN activates apoptosis.
The signature fall of cerebrospinal fluid concentrations of Aβ that herald Alzheimer’s may be preceded by a brief boost.
A new screening method detects interactions with mutated proteins that cause neurodegenerative disease.
Two large studies measured the occurrence of amyloid pathology in people with AD and other dementias. They confirm that amyloid may precede dementia onset by more than two decades, and rises with age, particularly in people with the ApoE4 gene.
Like other drug hopefuls for neurodegenerative disease, methylene blue staves off behavioral problems in transgenic mice only if given before memory begins to falter.
Using a viral vector, researchers created mice that express C9ORF72 hexanucleotide repeats in the brain.
In ALS motor neurons, antisense RNA foci outnumber the sense version, and correlate with a marker of pathology.
Denali Therapeutics gets off the ground with one of the largest Series A rounds ever.
Repeated activation of the perforant pathway over five months doubled the area of amyloid plaques in transgenic mice.
A revised plan of action for AD research has emerged from the Alzheimer’s Disease Research Summit 2015.